vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $21.9M, roughly 1.0× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -5.3%, a 12.5% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -9.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -5.3%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
BGSF vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $21.9M |
| Net Profit | $-1.2M | $1.6M |
| Gross Margin | 35.0% | — |
| Operating Margin | -17.6% | 9.0% |
| Net Margin | -5.3% | 7.2% |
| Revenue YoY | -9.4% | 1292.3% |
| Net Profit YoY | -18.2% | 116.7% |
| EPS (diluted) | $-0.12 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $21.9M | ||
| Q3 25 | $26.9M | $2.1M | ||
| Q2 25 | $23.5M | $3.0M | ||
| Q1 25 | $20.9M | $421.0K | ||
| Q4 24 | $24.3M | $1.6M | ||
| Q3 24 | $29.8M | $3.3M | ||
| Q2 24 | $25.7M | $2.7M | ||
| Q1 24 | $24.5M | $1.7M |
| Q4 25 | $-1.2M | $1.6M | ||
| Q3 25 | $-5.8M | $-7.4M | ||
| Q2 25 | $-3.7M | $-8.5M | ||
| Q1 25 | $-722.0K | $-12.3M | ||
| Q4 24 | $-981.0K | — | ||
| Q3 24 | $-804.0K | $-8.7M | ||
| Q2 24 | $-761.0K | $-10.2M | ||
| Q1 24 | $-792.0K | $-12.3M |
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | 9.0% | ||
| Q3 25 | -3.5% | -353.4% | ||
| Q2 25 | -18.8% | -292.3% | ||
| Q1 25 | 1.6% | -2921.4% | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -3.4% | -264.2% | ||
| Q2 24 | -5.7% | -390.6% | ||
| Q1 24 | 1.7% | -737.8% |
| Q4 25 | -5.3% | 7.2% | ||
| Q3 25 | -21.6% | -346.6% | ||
| Q2 25 | -15.9% | -287.1% | ||
| Q1 25 | -3.5% | -2911.4% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -2.7% | -259.6% | ||
| Q2 24 | -3.0% | -382.7% | ||
| Q1 24 | -3.2% | -719.1% |
| Q4 25 | $-0.12 | $0.05 | ||
| Q3 25 | $-0.52 | $-0.07 | ||
| Q2 25 | $-0.34 | $-0.09 | ||
| Q1 25 | $-0.06 | $-0.17 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.07 | $-0.17 | ||
| Q2 24 | $-0.07 | $-0.20 | ||
| Q1 24 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $26.4M |
| Total Assets | $57.8M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.1M | ||
| Q3 25 | $41.2M | $11.7M | ||
| Q2 25 | $2.8M | $27.5M | ||
| Q1 25 | $2.0M | $13.1M | ||
| Q4 24 | $32.0K | $22.5M | ||
| Q3 24 | $262 | $32.4M | ||
| Q2 24 | $226 | $30.0M | ||
| Q1 24 | $50 | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $48.1M | $26.4M | ||
| Q3 25 | $50.7M | $13.2M | ||
| Q2 25 | $78.3M | $18.2M | ||
| Q1 25 | $81.8M | $6.6M | ||
| Q4 24 | $82.3M | $17.5M | ||
| Q3 24 | $82.9M | $25.4M | ||
| Q2 24 | $83.2M | $21.6M | ||
| Q1 24 | $83.6M | $30.0M |
| Q4 25 | $57.8M | $42.2M | ||
| Q3 25 | $83.6M | $31.6M | ||
| Q2 25 | $149.7M | $40.7M | ||
| Q1 25 | $152.3M | $22.3M | ||
| Q4 24 | $150.1M | $32.2M | ||
| Q3 24 | $157.3K | $44.8M | ||
| Q2 24 | $159.8K | $42.3M | ||
| Q1 24 | $170.6K | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-1.1M |
| Free Cash FlowOCF − Capex | $1.7M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-1.1M | ||
| Q3 25 | $-4.8M | $-9.0M | ||
| Q2 25 | $2.2M | $-3.4M | ||
| Q1 25 | $1.1M | $-8.2M | ||
| Q4 24 | $3.2M | $-36.3M | ||
| Q3 24 | $6.5M | $-7.5M | ||
| Q2 24 | $7.3M | $-10.0M | ||
| Q1 24 | $7.4M | $-9.8M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $2.1M | $-3.4M | ||
| Q1 25 | $1.0M | $-8.3M | ||
| Q4 24 | $2.5M | $-36.4M | ||
| Q3 24 | $6.5M | $-7.5M | ||
| Q2 24 | $7.3M | $-10.0M | ||
| Q1 24 | $6.9M | $-9.8M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -18.1% | — | ||
| Q2 25 | 9.1% | -116.5% | ||
| Q1 25 | 5.0% | -1976.7% | ||
| Q4 24 | 10.2% | -2309.3% | ||
| Q3 24 | 21.7% | -225.7% | ||
| Q2 24 | 28.5% | -376.2% | ||
| Q1 24 | 28.1% | -573.0% |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.1% | 35.6% | ||
| Q4 24 | 3.0% | 4.2% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 2.0% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
